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ABSTRACT
Migraine adds to the burden of patients suffering from multiple sclerosis (MS). The ID-migraine is a useful tool for screening migraine, and 
the Migraine Disability Assessment questionnaire can evaluate disease burden. The aim of the present study was to assess the presence 
and burden of migraine in patients with MS. Methods: Patients diagnosed with MS attending specialized MS units were invited to answer an 
online survey if they also experienced headache. Results: The study included 746 complete responses from patients with MS and headache. 
There were 625 women and 121 men, and 69% of all the patients were aged between 20 and 40 years. Migraine was identified in 404 
patients (54.1%) and a moderate-to-high burden of disease was observed in 68.3% of the patients. Conclusion: Migraine is a frequent and 
disabling type of primary headache reported by patients with MS. 
Keywords: Migraine; headache; multiple sclerosis.
RESUMO
Enxaqueca piora o sofrimento do paciente que tem esclerose múltipla (EM). ID-migraine é uma ferramenta útil para seleção de pacientes 
com enxaqueca e Migraine Disability Assessment (MIDAS) é um questionário que avalia o impacto da doença. O objetivo do presente estudo 
foi avaliar a presença e impacto de enxaqueca em pacientes com EM. Métodos: Pacientes diagnosticados com EM e tratados em clínicas 
especializadas foram convidados a responder um questionário online se também apresentassem cefaleia. Resultados: O estudo incluiu 
746 participantes com cefaleia e EM que preencheram completamente as respostas. Foram 625 mulheres e 121 homens, sendo 69% dos 
pacientes com idade entre 20 e 40 anos. Enxaqueca foi identificada em 404 pacientes (54,1%) e moderado a grave impacto da doença foi 
observado em 68,3% dos casos. Conclusão: Enxaqueca é uma cefaleia primária frequente e incapacitante relatada por pacientes com EM.
Palavras-chave: Transtornos da enxaqueca; cefaleia; esclerose múltipla.
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Patients with multiple sclerosis (MS) are consistently 
reported as having a higher prevalence of headaches, partic-
ularly migraine1. The reason for this finding is yet to be clari-
fied, but the predominance of inflammatory cytokines and 
adverse events from medications rate high among the poten-
tial causes of increased prevalence of headache among MS 
patients2. In addition, demyelinating lesions in and around 
the periaqueductal grey area may be associated to (often 
intractable) headaches in patients with MS3,4. Adverse events 
relating to MS therapy may also account for the onset or 
worsening of migraine5,6.
The ID-Migraine is a simple three-item questionnaire 
that is used for screening migraine patients in primary care. 
However, it has only rarely been used in MS clinics7. It has 
been validated in several languages, including Brazilian 
Portuguese8. Only one previous study has investigated the 
potential use of ID-Migraine among patients with MS9. 
In this previous Italian study, ID-Migraine showed high sen-
sitivity (91%) and specificity (94%) for identifying migraine in 
144 patients with MS. The burden of migraine was assessed 
using the Migraine Disability Assessment (MIDAS)10, in the 
Brazilian validated version11. The MIDAS has already been 
used in a few studies on migraine in MS identifying a mod-
erate-to-high burden of disease12. Using these validated 
tools, the present study assessed headache in a population of 
Brazilian patients with MS. 
METHODS
This was a cross-sectional study carried out in special-
ized MS units. Ethics Committee approvals were obtained 
in accordance with the rules and regulations of each partic-
ipating MS center. Patients with MS attending regular con-
sultations at these centers were invited to reply to an online 
questionnaire that sought clinical and demographic data, 
headache characterization, ID-Migraine data and MIDAS 
responses. The neurologists in charge of the patients told 
them about the study and its characteristics, and patients’ 
associations in each region were informed of the national 
survey. The survey was set up in such a way that only the 
responses of patients who answered every question would 
be accepted for inclusion in the study. Nonetheless, these 
potential study participants were completely free to aban-
don the survey at all times. All information was obtained 
online without personal identification of patients: they 
were only asked to state their age, sex and number of years 
of formal schooling. 
Patients with episodic and chronic migraine and ten-
sion-type headache were diagnosed in accordance with 
the criteria of the International Headache Society (ICDH-3 
beta version)13. Details of these patients’ MS therapy 
were recorded. No healthcare professional had any influ-
ence on the responses that patients gave. Only patients 
with at least one year of confirmed diagnoses of MS were 
included in the study. The results are presented mainly in 
a descriptive manner.
RESULTS
Seven hundred and forty-six patients entered this study. 
The Table shows a summary of the results. There were 625 
women and 121 men, and 69% of all the patients were 
aged between 20 and 40 years. The majority of the patients 
(97.6%) had had 12 or more years of schooling and 70.9% 
of the sample were at university at the time or had already 
obtained a university degree. The duration of their MS was 
less than 10 years for 72.7% of all the patients. Migraine 
was identified in 404 patients with MS (54.1%), and ten-
sion-type headache affected 320 patients with MS (42.9%). 
Primary headache lasting longer than 15 days per month 
for more than three months was reported by 158 (21.1%) 
patients. Moderate or severe pain during the headache 
attacks were reported by 499 patients (69.9%). Headache 
identification was not possible in 22 patients and it was 
decided not to register “possible” or “probable” cases of a 
certain headache. 
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The ID-Migraine identified 409 individuals as migraineurs 
in this study. Using the ICDH-3 criteria, 404 patients with MS 
had all the necessary symptoms for diagnosing migraine. 
Thus, ID-Migraine presented 98.2% specificity, since five 
patients could be classified as having tension-type headache 
according to the IHS criteria but were identified as having 
migraine using this tool. The questionnaire showed 100% 
sensitivity, since no patients with migraine were identified 
using the ICDH-3 criteria that were not already identified 
through ID-Migraine. 
The MIDAS identified 276 cases of moderate or high 
disability among the 404 patients with migraine (68.3%). 
Migraine attacks were described as occurring on 7-15 days 
per month in 102 patients (25.2% of the migraineurs) and 
on more than 15 days per month in another 49 patients 
(12% of the migraineurs), and the presence of continuous 
headache was reported by a further 40 patients with 
MS (10% of the migraineurs). In summary, 47.2% of the 
patients with migraine and MS had at least seven days of 
pain per month.
Acetaminophen was the medication of choice for treating 
headache attacks for 36.1% of the patients, while 43.8% made 
use of metamizole sodium. Non-steroidal anti-inflammatory 
drugs were used by 34.3% of the patients. Oral tablets with 
ergot and caffeine were used by 30.6% of the patients who 
did not respond to the above-mentioned analgesics or anti-
inflammatory drugs. For refractory pain, triptans were used 
by 8.6% of the patients, while tramadol was used by 11.3%. All 
of these medications were often used in association with or 
in sequence for the same attack.
Prophylactic treatment with beta-blockers, topiramate, 
valproate or tricyclic drugs had been prescribed for 32.6% of 
the patients. Antidepressants, anti-anxiety drugs and other 
unspecific drugs had been used as preventive treatment for 
21.1% of the patients. However, this study was not designed 
to evaluate the effect of therapy among patients with MS.
Onset or worsening of headache episodes at or soon 
after receiving the diagnosis of MS was reported by 354 
patients (47.5%). Interferon beta was prescribed at some 
point during the therapy for 457 patients with MS in 
these units. Irrespective of the mode of administration 
of this drug (subcutaneously or intramuscularly), the use 
of interferon beta led to the onset or worsening of head-
ache in 266 patients (58.7% of those who used interferon 
beta at any point). On the other hand, glatiramer acetate 
was prescribed for 344 patients with MS at some point in 
their treatment and led to headache as an adverse event in 
14.4% of these individuals. Fingolimod led to the onset or 
worsening of previous headaches in 73.1% of 208 patients 
who received this treatment at any time, while natali-
zumab was reported to worsen headache in 58% of 190 
patients who were treated with this monoclonal antibody. 
Glatiramer acetate was the drug least related to headache 
as an adverse event (p < 0.001 in comparisons with inter-
feron beta, fingolimod and natalizumab). Other drugs had 
not been used in large enough numbers of patients to allow 
conclusions regarding headache triggering. There were 
only a few cases of patients using (or having used) teriflu-
nomide, dimethyl fumarate, alemtuzumab or ocrelizumab, 
because of the reimbursement system within the Brazilian 
Ministry of Health protocol for treating MS. This study was 
not designed to identify which type of headache was asso-
ciated with each of the treatments.
DISCUSSION
This large population study brought detailed informa-
tion on headache affecting 746 patients with MS. The five-
times higher prevalence of headache in women may be 
Table. Summarized data on patients with multiple sclerosis 
(MS) and headache. Results are presented as percentage, and 
absolute values are found in the text.










MS disease duration (years)
≤ 3 63.9%
> 3 36.1%
Had headache before MS?  
No 22.4%
Yes 77.6%
Headache onset or worsening after MS diagnosis?
No 52.5%
Yes 47.5%
Headache onset or worsening due to MS treatment?
No 44.6%
Yes  55.4%
Diagnosis of migraine by ID-Migraine and IHS 
criteria 54.1%
Diagnosis of tension type headache by IHS criteria 42.9%
Unclassifiable headache 3.0%
Moderate or high disability by migraine (MIDAS) 68.3%
≥ 15 days per month of headache 22.0%
F: female; M: male; IHS: International Headache Society; MIDAS: migraine 
disability assessment.
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due to the higher prevalence of both MS and headaches in 
women. Only for a small number of patients (< 3%) was it 
not possible to classify their headache through the online 
questionnaire. A similarly low number of unclassified head-
ache cases (2%) was observed in a recent large Turkish 
study14. The other patients in our study had either migraine 
or tension-type headache. 
The ID-Migraine was a sensitive and specific tool for 
screening migraine in patients with MS. Only one study 
had previously used ID-Migraine among patients with MS, 
and that study showed that the prevalence of migraine was 
53.5%9. In the present study, a similar prevalence of migraine 
was identified among patients with MS. 
The ID-migraine is an easy-to-use self-applicable test 
that can be routinely used in specialized MS centers. With 
this simple tool, patients in need of special attention for 
their headache can be identified and treated. Multiple scle-
rosis clinics tend to concentrate efforts on maintaining good 
neurological function, through assessing mobility, coordina-
tion, visual function, cognition, control of neuropathic pain 
(such as trigeminal neuralgia) and sphincter ability, but may 
not have any specific programs for attending to primary 
headaches. Both MS and migraine can negatively influence 
patients’ quality of life, mood, sleep and cognition. 
The burden of migraine in patients with MS was shown 
to be moderate or high in nearly 70% of these migraineurs. 
About a quarter of the migraineurs with MS suffered from 
headache attacks on 7-14 days every month. Over 21% of the 
migraineurs with MS had between 15 and 30 days of pain per 
month. The pain intensity was described as moderate or high 
in over 68% of the patients enrolled in this study. 
Most of the patients used analgesic and anti-inflammatory 
drugs to treat their attacks and less than one third of them 
had received prophylactic treatment for migraine. The dos-
age, duration and adherence to these prophylactic drugs was 
not established through the present study. Almost all the 
patients with MS participating in the present study treated 
their headache attacks mainly with painkillers and anti-
inflammatory drugs. This finding is in agreement with that 
reported by Villani et al.12, who also reported that the use of 
triptans by these patients was remarkably rare. These authors 
showed that less than 10% of the patients had received pro-
phylactic treatment for their migraine. In the present report, 
a larger number (nearly one third of all migraineurs) had 
received prophylaxis. However, the dose, duration and effi-
cacy of these preventive therapies cannot be assessed 
through the methodology used here.
Interferon beta, fingolimod and natalizumab seemed to 
increase the frequency and severity of headaches in patients 
with MS. Interferon beta has systematically been reported to 
be a triggering or worsening factor for migraine in patients 
with MS5,6,15. The present study identified headache as a fre-
quent adverse event of both fingolimod and natalizumab. 
In making therapeutic choices, these findings need to be 
considered, as some adverse events may deter the patients’ 
adherence to MS therapy. It is important to address migraine 
in patients with MS when aiming for a holistic approach to 
the well-being of people under neurologists’ care16,17. 
In conclusion, migraine is a frequent and disabling con-
dition in patients with MS. An adequate approach towards 
controlling both diseases is paramount if quality of life and 
adherence to treatment are sought.
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